Quarterly report pursuant to Section 13 or 15(d)

Related Party Transactions - Schedule of Effective Date and Equity Fee Payble (Detail)

v3.8.0.1
Related Party Transactions - Schedule of Effective Date and Equity Fee Payble (Detail)
 9 Months Ended
Sep. 30, 2017
Helocyte Inc [Member]  
Dividends, Paid-in-kind,Percentage 2.50%
Dividends Payable, Date Declared Mar. 20, 2015 [1]
Avenue Therapeutics, Inc. [Member]  
Dividends, Paid-in-kind,Percentage 2.50%
Dividends Payable, Date Declared Feb. 17, 2015 [1]
Mustang Bio, Inc [Member]  
Dividends, Paid-in-kind,Percentage 2.50%
Dividends Payable, Date Declared Mar. 13, 2015 [1]
Checkpoint Therapeutics, Inc [Member]  
Dividends, Paid-in-kind,Percentage 0.00% [2]
Dividends Payable, Date Declared Mar. 17, 2015 [1]
Cellvation Inc [Member]  
Dividends, Paid-in-kind,Percentage 2.50%
Dividends Payable, Date Declared Oct. 31, 2016 [1]
Caelum Biosciences, Inc. [Member]  
Dividends, Paid-in-kind,Percentage 2.50%
Dividends Payable, Date Declared Jan. 01, 2017 [1]
Cyprium Biosciences, Inc [Member]  
Dividends, Paid-in-kind,Percentage 2.50%
Dividends Payable, Date Declared Mar. 13, 2017 [1]
Aevitas Inc [Member]  
Dividends, Paid-in-kind,Percentage 2.50%
Dividends Payable, Date Declared Jul. 28, 2017 [1]
[1] Represents the effective date of each subsidiary’s Founders Agreement. Each PIK dividend and equity fee is payable on the annual anniversary of the effective date of the original Founders Agreement.
[2] Instead of a PIK dividend, Checkpoint pays the Company an annual equity fee in shares of Checkpoint’s common stock equal to 2.5% of Checkpoint’s fully diluted outstanding capitalization.